TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
August 02, 2022 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson...
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
July 11, 2022 16:05 ET
|
TransCode Therapeutics, Inc.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its...
TransCode Therapeutics to Participate at BIO International Convention
June 09, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June...
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
June 01, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors First SBIR program...
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
May 20, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person...
TransCode Therapeutics Acquires Option for Radiotheranostic Technology
May 19, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its...
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
May 16, 2022 08:30 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results...
TransCode Therapeutics’ CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
April 13, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce that its...
TransCode Therapeutics Reports 2021 Results; Provides Business Update
March 31, 2022 16:30 ET
|
TransCode Therapeutics, Inc.
BOSTON, March 31, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial...
TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®
March 25, 2022 12:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an...